Cargando…
Analysis of RET promoter CpG island methylation using methylation-specific PCR (MSP), pyrosequencing, and methylation-sensitive high-resolution melting (MS-HRM): impact on stage II colon cancer patient outcome
BACKGROUND: Already since the 1990s, promoter CpG island methylation markers have been considered promising diagnostic, prognostic, and predictive cancer biomarkers. However, so far, only a limited number of DNA methylation markers have been introduced into clinical practice. One reason why the vast...
Autores principales: | Draht, Muriel X. G., Smits, Kim M., Jooste, Valérie, Tournier, Benjamin, Vervoort, Martijn, Ramaekers, Chantal, Chapusot, Caroline, Weijenberg, Matty P., van Engeland, Manon, Melotte, Veerle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845472/ https://www.ncbi.nlm.nih.gov/pubmed/27118999 http://dx.doi.org/10.1186/s13148-016-0211-8 |
Ejemplares similares
-
Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review
por: Draht, Muriel X. G., et al.
Publicado: (2018) -
MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response
por: Switzeny, Olivier J., et al.
Publicado: (2016) -
Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing
por: Shaw, Richard J., et al.
Publicado: (2006) -
Dietary methyl donors, methyl metabolizing enzymes, and epigenetic regulators: diet–gene interactions and promoter CpG island hypermethylation in colorectal cancer
por: de Vogel, Stefan, et al.
Publicado: (2010) -
Body Size, Physical Activity and Risk of Colorectal Cancer with or without the CpG Island Methylator Phenotype (CIMP)
por: Hughes, Laura A. E., et al.
Publicado: (2011)